Every 10-Q that Jade Biosciences, Inc. (JBIO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow JBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JBIO filings page.
Jade Biosciences, Inc. reported a larger net loss as it invested heavily in its autoimmune biologics pipeline. For the three and six months ended June 30, 2026, net loss was $55.8 million and $96.1 million, compared to $32.1 million and $70.3 million in the prior-year periods. Operating expenses more than doubled year over year to $58.9 million for the quarter, driven mainly by higher research and development spending and stock-based compensation.
Cash and cash equivalents were $107.2 million and investments were $354.0 million, for total liquid resources of $461.2 million as of June 30, 2026. Management states this is sufficient to fund planned operating and capital needs for at least twelve months from the financial statement issuance date. Net cash used in operating activities was $67.7 million for the first half of 2026, while financing activities provided $192.7 million, including $162.1 million net from a June 2026 equity financing and $29.3 million from at-the-market share sales.
The company advanced its programs JADE101, JADE201, and JADE301. Positive interim Phase 1 data for JADE101 in healthy volunteers showed approximately 70% IgA reductions sustained at 12 weeks at a 700 mg subcutaneous dose, supporting potential every-12-week dosing in IgA nephropathy. Multiple milestone and royalty-bearing license agreements with Paragon and manufacturing arrangements with WuXi Biologics continue to structure future development and commercialization economics.
Jade Biosciences, Inc. reported a larger quarterly loss as it ramps up autoimmune drug development. For the three months ended March 31, 2026, the company recorded a net loss of $40.4 million, compared with $38.2 million a year earlier, driven mainly by higher research and development spending.
Research and development expenses rose to $36.1 million, and general and administrative costs increased to $7.4 million as Jade expanded its organization and pipeline. Operating cash outflow was $24.1 million in the quarter.
The balance sheet remains strong, with $55.1 million in cash and cash equivalents and $256.2 million in investments, totaling $311.3 million of liquid resources as of March 31, 2026. Management believes this will fund operating and capital needs for at least twelve months from the financial statement issuance date.
Jade is advancing three biologic candidates: JADE101 for IgA nephropathy, JADE201 for rheumatoid arthritis and other autoimmune diseases, and JADE301 targeting an undisclosed pathway, with multiple Phase 1 and Phase 2 trials expected to start or deliver interim data between 2026 and 2027.
Jade Biosciences (JBIO) reported third-quarter results reflecting active pipeline investment and a transformed capital structure following its reverse recapitalization with Aerovate and redomestication to Nevada. For the quarter ended September 30, 2025, net loss was $25.2 million, driven by research and development of $22.0 million and general and administrative of $5.4 million. Interest income was $2.3 million.
Liquidity strengthened: cash and cash equivalents were $50.1 million and investments were $148.8 million, totaling $198.9 million as of September 30, 2025. The company states these resources, combined with approximately $135 million of recent financing, are expected to fund at least 12 months of operations. Year-to-date operating cash use was $61.0 million. Capital actions included conversion of $129.2 million in convertible notes into equity and a pre-closing financing, with 7,375,394 pre-funded warrants outstanding at quarter-end. Shares outstanding were 46,004,205 as of November 7, 2025.
Jade Biosciences reported significant financing activity and operating losses in the quarter ended June 30, 2025. Cash and cash equivalents totaled $220.9 million at June 30, 2025, largely reflecting net proceeds of $190.5 million from the Pre-Closing Financing and cash acquired in the reverse recapitalization. Total assets were $223.97 million. The company recorded a net loss of $32.1 million for the three months and $70.3 million for the six months ended June 30, 2025. Operating expenses were $27.8 million for the quarter, including $22.5 million of research and development and $5.2 million of general and administrative expenses.
Corporate actions included a reverse recapitalization, redomestication to Nevada, conversion of $95.0 million of convertible notes into equity, issuance of Series A non-voting convertible preferred stock, and 32,626,730 shares outstanding as of August 8, 2025. The company stated its $220.9 million of cash is expected to fund operations for at least 12 months. Development programs include lead candidate JADE101 (APRIL) with first-in-human dosing planned in Q3 2025 and interim data expected H1 2026.